CSI Market
Sign In | Register

Cogent Biosciences Inc (COGT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access COGT quarterly Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Cogent Biosciences Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-328.94
Depreciation & amortization2.56
Amortization of Other Assets0.60
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets to be Disposed of0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation46.08
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt-7.18
Premiums Paid On Marketable Securities-
Marketable Securities Realized Gain Loss-
Increase Decrease In Operating Lease Right Of Use Asset-
Increase Decrease In Operating Leases-1.57
Operating Lease Right Of Use Asset Amortization Expense2.02
Debt Discount Included In Accrued Expenses And Other Liabilities0.02
Debt Issuance Costs Included In Accounts Payable And Accrued Expenses-
Offering Costs Included In Accounts Payable And Accrued Expenses0.06
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-2.51
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities10.69
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.20
Other Working Capital1.59
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities12.32
Discontinued operations0.00
Net Cash flow from Operating Activities-264.44
Investing Activities
Capital Expenditures-1.55
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities289.20
Payments to Acquire Marketable Securities-687.17
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-399.53
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-2.62
Long-term debt - borrowings-5.34
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock552.67
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-48.90
Proceeds From Issuance Underwritten Public Offering-
Payment To Contingent Value Right Holders-
Payments To Contingent Value Right Holders-
Proceeds From Issuance Of Common Stock And Preferred Stock Net Of Offering Costs-
Proceeds From Issuance Under At The Market Offering159.32
Proceeds From Convertible Senior Notes223.10
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities878.23
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-266.00
Total Cash Flow214.26
4 historic quarters locked

Sign in to unlock the full Cogent Biosciences Inc cash flow history.

Sign In Create Free Account

About Cogent Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 17, 2026
  • Source: cogt-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-053334

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License